ResMed closes $225m Propeller Health purchase

ResMed (NYSE:RMD) said yesterday that it completed its $225 million acquisition of Propeller Health and its digital medicine platform.

Lead by CEO David Van Sickle, Propeller will continue to operate as a standalone business within ResMed’s respiratory care portfolio, the companies reported.

ResMed first announced the deal in December, explaining that Propeller’s products for people with chronic obstructive pulmonary disease complement its suite of cloud-connected ventilators and establish the company as a leader in digital health solutions for COPD.

The addition of Propeller’s business is slated to have a dilutive impact on ResMed’s non-GAAP EPS of 1¢ to 2¢ per quarter during FY19, according to ResMed.

“I’m excited to welcome Propeller, a fellow digital health innovator and high-performing company, into the ResMed family,” ResMed CEO Mick Farrell said in prepared remarks.

“Propeller’s digital solutions and partnerships strengthen ResMed’s larger suite of products that can treat millions of people at various stages of their COPD and other chronic diseases, all aimed at improving people’s quality of life, while reducing the effects of these diseases, hospitalizations, and the overall cost of healthcare,” Farrell added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW